Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug

Published on January 11, 2022

Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.

Continue reading on website
Other news

The Zacks Analyst Blog Highlights: SPY, VV, VTI, TQQQ and XLF

January 11, 2022
SPY, VV, VTI, TQQQ and XLF are included in this analyst blog.

The Zacks Analyst Blog Highlights: Nikon, Computer Task Group, Toyota Motor, Mitsui & Co. and Dillard's Inc

January 11, 2022
Nikon, Computer Task Group, Toyota Motor, Mitsui & Co. and Dillard's Inc are included in this analyst blog.